Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
Joint Authors
Yokoyama, Hirokazu
Ebinuma, Hirotoshi
Oikawa, Yoichi
Shimada, Akira
Kikuchi, Masahiro
Irie, Junichiro
Itoh, Hiroshi
Tomita, Kengo
Saito, Hidetsugu
Hirose, Hiroshi
Kawai, Toshihide
Ojiro, Keisuke
Hirata, Takumi
Hibi, Toshifumi
Source
International Journal of Endocrinology
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-08-13
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Aim.
This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus.
Methods.
This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan.
Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n=12) or losartan at a dose of 50 mg once a day (n=7) for 12 months.
Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months.
Results.
The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87±0.26 to 0.59±0.22 mEq/L (mean ± SD), P=0.005) and a significant increase in L/S ratio (P=0.049) evaluated by CT scan, while these parameters were not changed in the losartan group.
Conclusion.
Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”dx.doi.org/10.1155/2014/302602
American Psychological Association (APA)
Hirata, Takumi& Tomita, Kengo& Kawai, Toshihide& Yokoyama, Hirokazu& Shimada, Akira& Kikuchi, Masahiro…[et al.]. 2013. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology،Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-483000
Modern Language Association (MLA)
Hirata, Takumi…[et al.]. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology No. 2013 (2013), pp.1-9.
https://search.emarefa.net/detail/BIM-483000
American Medical Association (AMA)
Hirata, Takumi& Tomita, Kengo& Kawai, Toshihide& Yokoyama, Hirokazu& Shimada, Akira& Kikuchi, Masahiro…[et al.]. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology. 2013. Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-483000
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-483000